nach oben

Erschienen in:

01.08.2010 | Original Article

Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption

verfasst von: M. Matsubara, E. Yamachika, H. Tsujigiwa, N. Mizukawa, T. Ueno, J. Murakami, N. Ishida, Y. Kaneda, N. Shirasu, S. Takagi

Erschienen in: Osteoporosis International | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Summary

The main component of the metabolic by-products of fermentation by Propionibacterium freudenreichii ET-3 is 1,4-dihydroxy-2-naphthoic acid (DHNA), which has a naphthoquinone skeleton, as in vitamin K2. This study showed that DHNA improved bone mass reduction with osteoporosis model mice caused by FK506.

Introduction

Growth of the intestinal bacterium Lactobacillus bifidus is specifically facilitated by DHNA. The present study used osteoporosis model mice to investigate the effects of DHNA on bone remodeling.

Methods

FK506, an immunosuppressant, was used to prepare osteoporosis model mice. Thirty mice were divided into three groups: FK group, FK+DHNA group, and control group. In the FK group, FK506 was administered to induce bone mass reduction. In the FK-DHNA group, FK506 and DHNA were administered concurrently to observe improvements in bone mass reduction. To ascertain systemic and local effects of DHNA, we investigated systemic pathological changes in colon, kidney function and cytokine dynamics, and morphological and organic changes in bone and osteoclast dynamics as assessed by culture experiments.

Results

Compared to the FK group without DHNA, colon damage and kidney dysfunction were milder for FK+DHNA group, and production of inflammatory cytokines (interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α) was more suppressed. Furthermore, compared to the group without DHNA, histological analyses and radiography showed that bone resorption was suppressed for the DHNA group. Culture experiments using osteoclasts from murine bone marrow showed osteoclast suppression for the DHNA group compared to the group without DHNA.

Conclusion

These results show that DHNA has some effects for improving bone mass reduction caused by FK506.

Kanis JA, Melton LJ 3rd, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141CrossRefPubMed

Roodman DG (1996) Advances in bone biology: the osteoclast. Endocrine Rev 17:308–332

Rodino MA, Shane E (1998) Osteoporosis after organ transplantation. Am J Med 104:459–469CrossRefPubMed

Kawaguchi H, Manabe N, Miyaura C et al (1999) Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 104:229–237CrossRefPubMed

Cohen A, Shane E (2003) Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617–630CrossRefPubMed

Monegal A, Navasa M, Guañabens N et al (2001) Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484–492CrossRefPubMed

Kirino S, Fukunaga J, Ikegami S et al (2004) Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J Bone Miner Res 22:554–560CrossRef

Fukunaga J, Yamaai T, Yamachika E et al (2004) Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. Bone 34:425–431CrossRefPubMed

Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Tranaplantation 63:977–983CrossRef

10.

Hengming K, Huai Q (2003) Structures of calcineurin and its complexes with immunophilins–immunosuppressants. Biochem Biophys Res Commun 311:1095–1102CrossRef

11.

Liu J, Farmer JD, Lane WS et al (1991) Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes. Cell 66:807–815CrossRefPubMed

12.

Goto T, Kino T, Hatanaka H et al (1991) FK506: historical perspectives. Transplant Proc 23:2713–2717PubMed

13.

Fruman DA, Klee CB, Bierer BE et al (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine A. Proc Natl Acad Sci USA 89:3686–3690CrossRefPubMed

14.

Cohen A, Sambrook P, Shane E (2004) Management of bone loss after organ transplantation. J Bone Miner Res 19:1919–1932CrossRefPubMed

15.

Shane E, Addesso V, Namerow PB et al (2004) Alendronateversus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767–776CrossRefPubMed

16.

Crawford BA, Kam C, Pavlovic J et al (2006) Zoledronic acidprevents bone loss after liver transplantation: a　randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239–248PubMed

17.

Atamaz F, Hepguler S, Akyildiz M et al (2006) Effects of　alendronate on bone mineral density and bone metabolic　markers　in patients with liver transplantation. Osteoporos Int 17:942–949CrossRefPubMed

18.

de Nijs RNJ, Jacobs JWG, Algra A et al (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporosis Int 15:589–602CrossRef

19.

Fukunaga M, Kushida K, Kishimoto H et al (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971–979CrossRefPubMed

20.

Green JR, Seltenmeyer Y, Jaeggi KA et al (1997) Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol. 80:225–230CrossRefPubMed

21.

Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676–1679CrossRefPubMed

22.

Mehrotra B, Ruggiero S (2006) Bisphosphonate complications including osteonecrosis of the jaw. Hematology 2006:356–360CrossRef

23.

Yarom N, Yahalom R, Shoshani Y et al (2007) Osteonecrosis of the jaw induced by orally administered bisphospnates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18:1363–1370CrossRefPubMed

24.

Bagan J, Blade J, Cozar JM et al (2007) Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 12:336–340

25.

Dempfle CE, Borggrefe M (2005) Vermeidung von Notfallsituationen bei gerinnungshemmender Therapie mit Vitamin-K-Antagonisten. Der Internist 46:1006–1013CrossRefPubMed

26.

Okada Y, Tsuzuki Y, Miyazaki J, Miura S et al (2006) Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut 55(5):681–688CrossRefPubMed

27.

Kaneko T, Mori H, Iwata M et al (1993) Growth stimulator for bifidobacteria produced by Propionibacterium freudenreichii and several intestinal bacteria. J Dairy Sci 77:393–404CrossRef

28.

Kaneko T (1999) A novel bifidogenic growth stimulator produced by Propionibacterium freudenreichii. Bioscience Microflora 18(2):73–80

29.

Suzuki A, Mitsuyama K, Koga H et al (2006) Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrion 22(1):76–81CrossRef

30.

Nanbara A, Nukada R, Nagai S (1983) Inhibition by acetic and propionic acids of the growth of Propionibacterium shermanii. J Ferment Technol 61:551–556

31.

Iwasa K, Hojo K, Yoda N et al (2002) Isolation and identification of a new bifidogenic growth stimulator produced by Propionibacterium freudenreichii ET-3. Biosci Biotechnol Biochem 66(3):679–681CrossRef

32.

Iwamoto J, Takeda T, Sato Y et al (2007) Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats. Exp Anim 56(2):103–110CrossRefPubMed

33.

Kinoshita Y, Taguchi M, Takeshita A et al (2005) 1,25-Dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis. J Clin Endocrinol Metab 90(12):6727–6731CrossRefPubMed

34.

Gal-Moscovici A, Sprague SM, Lerma EV (2007) Treatment of renal osteodystrophy. Clin Rev Bone Mineral Metab 5:27–38CrossRef

35.

Mrvos R, Hodgman M, Krenzelok EP (1997) Tacrolimus (FK506) overdose: a report of five cases. J Toxicol Clin Toxicol 35(4):395–399CrossRefPubMed

36.

Jimi E, Nakamura I, Duong LT et al (1999) Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247:84–93CrossRefPubMed

37.

Akatsu T, Takahashi N, Udagawa N et al (1991) Role of prostaglandins in interleukin-1 bone resorption in mice vitro. J Bone Miner Res 6:183–190CrossRefPubMed

38.

Kobayashi K, Takahashi N, Jimi E et al (2000) Tumor necrosis factor stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL–RANK interaction. J Exp Med 191(2):275–286CrossRefPubMed

39.

Azuma Y, Kaji K, Katogi R et al (2000) Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275(7):4858–4864CrossRefPubMed

40.

Gordon CM, Binello E, LeBoff MS et al (2006) Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokinesand bone density in cystic fibrosis. Osteoporos Int 17:783–790CrossRefPubMed

Titel: Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption
verfasst von: M. Matsubara
E. Yamachika
H. Tsujigiwa
N. Mizukawa
T. Ueno
J. Murakami
N. Ishida
Y. Kaneda
N. Shirasu
S. Takagi
Publikationsdatum: 01.08.2010
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 8/2010
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-1075-y

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Knie-TEP: Kein Vorteil durch antibiotikahaltigen Knochenzement

29.05.2024 Periprothetische Infektionen Nachrichten

Zur Zementierung einer Knie-TEP wird in Deutschland zu über 98% Knochenzement verwendet, der mit einem Antibiotikum beladen ist. Ob er wirklich besser ist als Zement ohne Antibiotikum, kann laut Registerdaten bezweifelt werden.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption